Presidential Trainee Showcase

Join ASCPT President, Issam Zineh, PharmD, MPH, as he recognizes the 2022 Presidential Trainee Recipients.

Then proceed to the ePoster Gallery to explore the Presidential Trainee Posters and participate in an interactive video chat Q&A with the presenters.

PT-001 - COMPARATIVE ANALYSIS OF THE RB PATHWAY IN LEIOMYOSARCOMA
Monica Bennett, BS

PT-002 - DEVELOPMENTAL PHARMACOKINETICS AND PHARMACOGENOMICS OF ISONIAZID IN PREDOMINANTLY LOW-BIRTH-WEIGHT OR PRETERM INFANTS WITH OR WITHOUT HIV EXPOSURE
Agathe Béranger, MD, PhD

2022 Jason Morrow, MD Presidential Trainee Award Recipient
PT-003 - CORONARY HEART DISEASE POLYGENIC RISK SCORE MODIFIES STATIN RELATIVE RISK REDUCTION FOR THE PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN A REAL-WORLD COHORT
Mari Cayabyab, PharmD

PT-004 - PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF PRIMARY CLINICAL OUTCOMES IN TREATING DRUG-SENSITIVE TUBERCULOSIS WITH FOUR-MONTH HIGH-DOSE RIFAPENTINE WITH AND WITHOUT MOXIFLOXACIN (STUDY 31/A5349)
Vincent Chang, BS

PT-005 - IDENTIFICATION OF A DISTAL ENHANCER AND REGULATORY VARIANTS CONTROLLING EXPRESSION OF THE CYP3A GENES
Joseph Collins, PhD

PT-006 - HYPOALBUMINEMIA EARLY IN TREATMENT HINDERS BENEFIT FROM IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED CANCERS
Yizhen Guo, PharmD

PT-007 - OPTIMIZING DIHYDROARTEMISININ-PIPERAQUINE REGIMENS FOR MALARIA PREVENTION IN PREGNANT WOMEN USING REPEATED ECG AND PARASITE DENSITY MEASURES
Emma Hughes, BA

PT-008 - PHARMACOGENOMIC GENOME-WIDE META-ANALYSIS TO IDENTIFY VARIANTS ASSOCIATED WITH THIAZIDE AND THIAZIDE-LIKE DIURETIC INDUCED GLUCOSE CHANGE
Noor A. Nahid, BS, MS

PT-009 - PREVENTION OF OXALIPLATIN NEUROPATHY BY DULOXETINE-MEDIATED OCT2 INHIBITION
Mahesh Nepal, PhD

PT-010 - WEIGHT-BASED DOSING IS NOT NEEDED FOR RIFAMPICIN FOR PATIENTS WITH TUBERCULOSIS (TB): PK EVIDENCE FROM TBTC STUDY S31/A5349 (STUDY S31)
Huy Ngo, PharmD, PhD

PT-011 - INVESTIGATION OF CARDIOVASCULAR OUTCOMES IN BLACK PATIENTS FOLLOWING IMPLEMENTATION OF CYP2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN A REAL-WORLD CLINICAL SETTING
Anh Nguyen, PharmD

2022 David J. Goldstein, MD, PhD Presidential Trainee Award
PT-012 - PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL)
Nam Nguyen, PharmD

PT-013 - CORTISOL REGULATES ALTERNATIVE POLYADENYLATION IN A GENOTYPE-DEPENDENT MANNER: GLUCOCORTICOID-DEPENDENT PHARMACOGENOMIC ALTERNATIVE POLYADENYLATION QUANTITATIVE TRAIT LOCI (PGx-3’aQTLs)
Thanh Thanh Nguyen, BA

PT-014 - RISK STRATIFICATION WITH PRE-TREATMENT METABOLITE RISK SCORE FOR CARFILZOMIB-RELATED CARDIOTOXICITY IN MULTIPLE MYELOMA PATIENTS
Trang Nguyen, PharmD

PT-015 - CHARACTERIZATION OF CAR-T CELLULAR KINETICS AND EFFICACY IN PATIENTS WITH SOLID TUMORS IN PRESENCE OR ABSENCE OF PRIOR LYMPHODEPLETION CHEMOTHERAPY USING A PBPK-PD MODEL
Keyur Parmar, MS

PT-016 - POLYGENIC RISK SCORES FOR BLOOD PRESSURE MAY PREDICT RISK OF SEVERE BEVACIZUMAB-INDUCED HYPERTENSION IN CANCER PATIENTS
Julia Quintanilha, PharmD, PhD

PT-017 - CLINICAL PHARMACOLOGY POSTMARKETING STUDIES: A US FDA EVALUATION OF KNOWLEDGE GAPS AND TRANSLATION INTO LABELING
Sarah Ridge, PhD

PT-018 - A POLYGENIC DNA DAMAGE REPAIR PHARMACOGENOMICS (DDR_PGX) SCORE PREDICTS RESPONSE TO GEMTUZUMAB OZOGAMICIN IN PEDIATRIC AML PATIENTS
Vivek Shastri, PhD

PT-019 - UNCOVERING THE DISPROPORTIONAL IMPACT OF CHRONIC KIDNEY DISEASE ON THE RENAL SECRETION OF DRUGS VIA ORGANIC ANION TRANSPORTERS (OAT) 1 AND 3
Shawn Pei Feng Tan, BS

PT-020 - IMPACT OF CYP2C19 GENOTYPE ON PREDICTION OF CARDIOVASCULAR EVENTS WITH THE ABCD-GENE SCORE AMONG PATIENTS RECEIVING CYP2C19-GUIDED ANTIPLATELET THERAPY AFTER PCI
Cameron Thomas, PharmD

PT-021 - DEVELOPMENT OF A TRANSLATIONAL PBPK-PD FRAMEWORK TO CHARACTERIZE CELLULAR KINETICS AND BIODISTRIBUTION OF CAR-T CELLS IN MICE AND CANCER PATIENTS
Angelia Wang, BS, MS